Table 1. Trials Included in Meta-Analyses

Trial	**Population**	**Recruitment Period**	**Arms**	**n**
RTOG 8610[8]	T2c-4 ≥25cm^2 Node+ allowed if below CI	1987-1991	2 mo ADT -> 70 Gy RT + 2 mo ADT vs. 70 Gy RT alone	456
EORTC 22863[9]	T1-T2 WHO grade 3 T3-4	1987-1995	70 Gy RT + 36 mos ADT vs. 70 Gy RT alone	403
RTOG 9202[10]	T2c-T4 AND PSA<150	1992-1995	2 mo ADT -> 65-70 Gy RT + 28 mo ADT vs. 2 mo ADT -> 65-70 Gy RT + 2 mo ADT	1456
RTOG 9408[11]	T1b-T2b and PSA≤20	1994-2001	2 mo ADT -> 66.6 Gy RT + 2 mo ADT vs. 66.6 Gy RT alone	1974
TROG 9601[12]	T2b,T2c,T3,T4	1996-2008	2 mo ADT -> 66 Gy RT + 1 mo ADT vs. 66 Gy RT alone 5 mo ADT -> 66 Gy RT + 1 mo ADT vs. 66 Gy RT alone	802
EORTC 22961[13]	T1c-T2a-B pN1-N2 T2c-T4 N0-N2 with PSA<40x UNL	1997-2001	70 Gy RT + 36 mo ADT vs. 70 Gy RT + 6 mo ADT	910
CKVO9610[4]	T1b-T4, PSA <60	1997-2003	68 Gy RT vs. 78 Gy RT, with 0, 6, or 36 mo ADT	664
MRC RT01[5]	T1b-T3a	1998-2001	3-6 mo ADT + 64 Gy RT vs. 3-6 mo ADT + 74 Gy RT	843
DART/GICOR[14]	T1c-T3b with NCCN intermediate or high risk and PSA<100	2000-2004	2 mo ADT -> 78 Gy RT + 28 mo vs. 2 mo ADT -> 78 Gy RT + 2 mo ADT	352
PCSIII[6]	Intermediate risk ≤80 years	2000-2010	4 mo ADT → 70 Gy RT + 2 mo ADT vs. 76 Gy RT alone vs. 4 mo ADT → 76 Gy RT + 2 mo ADT	600
EORTC 22991[21]	T1b-T2a PSA>10 AND GS≥7 T2b-T4 and PSA up to 12.5x UNL	2001-2008	70-78 Gy RT + 6 mo ADT vs. 70-78 Gy RT alone	819
RTOG 0126[7]	T1b-T2b and GS 6 and PSA 10-20 GS 7 and PSA <15	2002-2008	70.2 Gy RT vs. 79.2 Gy RT	1532
TROG RADAR[15]	T2b-T4 T2a if GS≥7 and PSA ≥10	2003-2007	5 mo ADT -> 66-74 RT + 13 mo ADT vs. 5 mo ADT -> 66-74 RT + 1 mo ADT (with some patients receiving 46 Gy + HDR)	1051

Abbreviations: ADT, androgen deprivation therapy; CI, common iliac; CKVO9610, CKVO9610 trial from the Dutch Cancer Society; DART/GICOR, DART trial from the Grupo de Investigación Clínica en Oncología Radioterápica; EORTC, European Organisation for Research and Treatment of Cancer; GS, Gleason score; HDR, high dose-rate brachytherapy; ICORG, Ireland Cooperative Oncology Research Group; MRC, MRC RT01, MRC RT01 trial from the Medical Research Council; NCCN, National Comprehensive Cancer Network; PCS, Prostate Cancer Study; PSA, prostate-specific antigen; RT, radiotherapy; RTOG, Radiation Therapy Oncology Group; TROG, Trans-Tasman Radiation Oncology Group; UNL, upper normal limit; WHO, World Health Organization

Table 2. Patient Characteristics

Parameter	All Patients (n=11862)	Low Dose RT (n=2820)	Low Dose RT + STADT (n=3960)	Low Dose RT + LTADT (n=1695)	High Dose RT (n=1535)	High Dose RT+STADT (n=1383)	High Dose RT+LTADT (n=469)	p-value*
Follow-up (year), Median (IQR)	**8.81(5.7-11.5)**	8.6 (5.4-11.6)	9.3 (5.8-12)	7.7 (5.2-11.5)	8.8 (6.7-10.8)	9.5 (6.3-11.3)	7.5 (5.2-10.6)	<0.001
Age at treatment (year), Median (IQR)	**70 (65-74)**	70 (65-74)	70 (65-73.8)	70 (65-74)	70 (65-74)	69 (64.3-73)	69.6 (64.3-73.8)	<0.001
NCCN Risk Group								<0.001
High	**5373 (45%)**	799 (28.9%)	2079 (53.3%)	1425 (84.7%)	191 (12.4%)	552 (40.1%)	327 (69.7%)	
Intermediate	**5305 (45%)**	1594 (57.6%)	1382 (35.4%)	247 (14.7%)	1246 (81.2%)	694 (50.4%)	142 (30.3%)	
Low	**1056 (9%)**	374 (13.5%)	442 (11.3%)	10 (0.6%)	98 (6.4%)	132 (9.6%)	0 (0%)	
Gleason Score (%)								<0.001
6	**4623 (39%)**	1170 (43.2%)	1859 (48.5%)	596 (38.4%)	459 (30.2%)	490 (36.4%)	49 (10.4%)	
7	**5033 (42%)**	1248 (46.1%)	1335 (34.8%)	573 (36.9%)	996 (65.5%)	630 (46.8%)	251 (53.5%)	
8	**1074 (9%)**	179 (6.6%)	381 (9.9%)	221 (14.2%)	51 (3.4%)	148 (11%)	94 (20%)	
9	**610 (5%)**	100 (3.7%)	217 (5.7%)	141 (9.1%)	12 (0.8%)	69 (5.1%)	71 (15.1%)	
10	**91 (1%)**	13 (0.5%)	41 (1.1%)	21 (1.4%)	2 (0.1%)	10 (0.7%)	4 (0.9%)	
iPSA (ng/mL), Median (IQR)	**11.4 (7.2-19)**	9.3 (6.1-14.2)	12.2 (7.7-21)	18 (10.2-35)	9 (5.9-13)	11.8 (7.5-18.4)	14 (8.5-22.5)	<0.001
T stage category (%)								<0.001
T1/T2	**8101 (68%)**	2278 (81.5%)	2462 (62.7%)	520 (30.7%)	1444 (95%)	1120 (83%)	277 (59.1%)	
T3/T4	**3651 (31%)**	516 (18.5%)	1463 (37.3%)	1175 (69.3%)	76 (5%)	229 (17%)	192 (40.9%)	

iPSA, initial prostate-specific antigen; IQR, interquartile range; LTADT, long-term androgen deprivation therapy; NCCN, National Comprehensive Cancer Network; RT, radiotherapy; STADT, short-term androgen deprivation therapy; T, tumor classification.

Table 3. Selected Pairwise Comparisons from the Network Meta-Analysis Evaluating Impact of Escalating Radiation Dose, Adding Androgen Deprivation Therapy, or Prolonging Androgen Deprivation Therapy

	MFS		BCRFS		OS	
	HR (95%CI)	**p-value**	**HR (95%CI)**	**p-value**	**HR (95%CI)**	p-value
Low Dose RT + LTADT vs. Low Dose RT + STADT	0.73 (0.62, 0.86)	<0.001	0.62 (0.52, 0.74)	<0.001	0.83 (0.73, 0.95)	0.01
Low Dose RT + STADT vs. Low Dose RT	0.82 (0.72, 0.95)	<0.01	0.67 (0.57, 0.79)	<0.001	0.86 (0.77, 0.96)	<0.001
Low Dose RT + LTADT vs. Low Dose RT	0.60 (0.49, 0.73)	<0.001	0.42 (0.34, 0.52)	<0.001	0.71 (0.61, 0.84)	<0.001
High Dose RT + LTADT vs. High Dose RT + STADT	0.69 (0.51, 0.93)	0.03	0.65 (0.48, 0.86)	<0.01	0.70 (0.53-0.93)	0.02
High Dose RT + STADT vs. High Dose RT	0.85 (0.68, 1.06)	0.13	0.65 (0.52, 0.81)	<0.001	0.89 (0.73-1.09)	0.27
High Dose RT + LTADT vs. High Dose RT	0.58 (0.40, 0.84)	<0.01	0.40 (0.28-0.58)	<0.001	0.63 (0.44-0.88)	0.01
High Dose RT vs. Low Dose RT	0.97 (0.80, 1.18)	0.70	0.78 (0.64, 0.95)	0.02	0.97 (0.82, 1.15)	0.50
High dose RT + STADT vs. Low dose RT + STADT	0.99 (0.80, 1.23)	0.97	0.75 (0.61-0.93)	0.01	0.98 (0.82, 1.19)	0.98
High dose RT + LTADT vs. Low dose RT + LTADT	0.94 (0.64, 1.36))	0.98	0.77 (0.54-1.11)	0.16	0.83 (0.58, 1.18)	0.31

BCRFS, biochemical recurrence-free survival; CI, confidence interval; HR, hazard ratio; LTADT, long-term androgen deprivation therapy; MFS, metastasis-free survival; OS, overall survival; RT, radiotherapy; STADT, short-term androgen deprivation therapy.